Etienna Bio Secures Exclusive Worldwide License from UMass Chan Medical School for Novel Adipose-Derived Regenerative PlatformLEAWOOD, Kan., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Etienna Bio, Inc., a biotechnology company focused on next-generation autologous and cell-enabled biomaterials for regenerative and aesthetic applications, today announced that it has entered into an exclusive, worldwide license agreement with the UMass Chan Medical School to develop and commercialize a proprietary adipose-derived cellular and matrix technology platform.
